Impact of Financial Incentives
Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Feb 15, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how financial incentives can help clinics improve communication with families and increase the number of children getting the HPV vaccine. Some clinics will receive training to enhance their communication skills, while others will receive both training and a financial incentive program, along with monthly reports to track their progress. The goal is to see if these strategies can lead to more children getting vaccinated against HPV, which can help prevent certain types of cancers.
To participate in this trial, clinics in North Carolina must meet specific criteria, such as having a low HPV vaccination rate (less than 72%) and serving at least 50 patients aged 9 to 12. The trial will not involve enrolling children directly; instead, vaccination data from children who are already patients at these clinics will be analyzed. It's important to note that clinics that have recently used financial incentives or communication training for HPV vaccinations will not be eligible. Overall, this trial aims to find effective ways to increase HPV vaccination rates among children, ultimately improving their health and well-being.
Gender
ALL
Eligibility criteria
- • This trial will enroll clinics and intervene with clinical staff. We will use vaccination data from children to evaluate intervention effectiveness. We will not enroll children or interact with them directly.
- Inclusion Criteria:
- Clinics are eligible if they are a pediatric or family medicine clinic in North Carolina that in the past year had:
- • less than 72% HPV vaccine initiation rate,
- • greater than or equal to 50 patients ages 9-12
- • greater than or equal to 2 HPV vaccine providers
- • no clinic or provider-level financial incentive programs to increase system, clinic, or provider HPV vaccination rates among patients aged 9-12 in the past two years, and
- • no HPV vaccine provider communication trainings in the past six months.
- Children's medical records will be eligible to be included in the dataset if children:
- • are between the ages of 9-12 years at baseline and
- • are attributed to a participating clinic at 12- or 24-month follow-up.
- Exclusion Criteria:
- Clinics are excluded if they:
- • do not provide HPV vaccine to children ages 9-12
- • have a specialty other than pediatrics or family medicine
- • had an HPV vaccine-specific financial incentive program in the past two years
- • had a formal HPV vaccine communication training in the past 6 months
- • had an HPV initiation rate greater than 72$
- • had fewer than 49 patients aged 9-12
- • had 1 or fewer HPV vaccine providers
- Children's medical records will not be eligible to be included in the dataset if children:
- • are not between the ages of 9-12 years at baseline
- • are not attributed to a participating clinic at 12- or 24-month follow-up
About Unc Lineberger Comprehensive Cancer Center
The UNC Lineberger Comprehensive Cancer Center is a leading research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials and comprehensive patient care. As a National Cancer Institute-designated comprehensive cancer center, it integrates cutting-edge research, interdisciplinary collaboration, and patient-centered approaches to address diverse oncology challenges. With a commitment to translating scientific discoveries into effective therapies, UNC Lineberger strives to improve outcomes for patients while fostering a robust environment for education and training in cancer research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chapel Hill, North Carolina, United States
Chapel Hill, North Carolina, United States
Patients applied
Trial Officials
Justin G Trogdon, PhD
Principal Investigator
University of North Carolina, Chapel Hill
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials